Table 3.
Comparison of HIV-related characteristics between high and low functioning groups by each assessment tool.
| Characteristic | Functional Status Group by Assessment Tool
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fried’s Frailty Phenotype | P value | Short Physical Performance Battery | P value | 400-m walk | P value | ||||
| High N=167 (%) |
Low N=27 (%) |
High N=223 (%) |
Low N=26 (%) |
High N=166 (%) |
Low N=11 (%) |
||||
| Years since HIV diagnosis (mean, standard error) | 14.5 (0.6) | 15.5 (1.5) | 0.54 | 14.2 (0.5) | 16.2 (1.6) | 0.25 | 14.4 (0.6) | 17.9 (2.3) | 0.17 |
| History of AIDS | 105 (63) | 21 (78) | 0.19 | 143 (64) | 18 (69) | 0.67 | 97 (58) | 7 (64) | 0.77 |
| Prior opportunistic infection | 60 (36) | 10 (37) | 1.0 | 74 (33) | 7 (27) | 0.67 | 55 (33) | 2 (18) | 0.35 |
| Lipoatrophy | 32 (19) | 5 (19) | 1.0 | 48 (22) | 7 (27) | 0.62 | 32 (19) | 2 (18) | 1.0 |
| Risk for HIV acquisition | |||||||||
| MSMa | 113 (68) | 19 (70) | 0.83 | 148 (66) | 11 (42) | 0.02 | 118 (71) | 5 (45) | 0.09 |
| Intravenous drug use | 21 (13) | 3 (11) | 1.0 | 35 (16) | 4 (15) | 1.0 | 22 (13) | 2 (18) | 0.65 |
| Heterosexual | 45 (27) | 4 (15) | 0.24 | 56 (25) | 9 (35) | 0.35 | 41 (25) | 3 (27) | 1.0 |
| Other | 6 (4) | 2 (7) | 0.60 | 9 (4) | 4 (15) | 0.04 | 7 (4) | 2 (18) | 0.1 |
| CD4+ T-cells/μL (geometric mean, 95% CIb) | 556 (514–601) | 459 (344–613) | 0.20 | 516 (477–559) | 448 (345–580) | 0.29 | 517 (469–570) | 542 (376–782) | 0.79 |
| Current CD4+ lymphocyte count <200 cells/μL | 3 (2) | 3 (11) | 0.04 | 15 (7) | 3 (12) | 0.41 | 11 (7) | 0 (0) | 0.63 |
| Nadir CD4+ T-cells/μL (geometric mean, 95% CIb) | 88 (69–112) | 58 (34–99) | 0.15 | 91 (74–111) | 75 (44–128) | 0.50 | 99 (78–124) | 112 (51–249) | 0.73 |
| Viral load “blip” | 23 (14) | 4 (15) | 1.0 | 33 (15) | 3 (12) | 0.78 | 20 (12) | 0 (0) | 0.37 |
| VACSc Index Score (mean, standard error) | 15.1 (0.9) | 23.8 (3.8) | 0.03 | 15.8 (0.9) | 28.2 (3.4) | 0.001 | 15.8 (1.0) | 27.6 (6.0) | 0.08 |
| Current use of: | |||||||||
| NRTId | 161 (97) | 25 (93) | 0.25 | 217 (97) | 26 (100) | 0.63 | 162 (98) | 11 (100) | 1.0 |
| NNRTIe | 72 (43) | 13 (48) | 0.68 | 99 (44) | 12 (46) | 1.0 | 76 (46) | 7 (64) | 0.35 |
| Protease inhibitor | 82 (49) | 17 (63) | 0.22 | 115 (52) | 11 (42) | 0.41 | 83 (50) | 3 (27) | 0.21 |
| Integrase inhibitor | 37 (22) | 4 (15) | 0.46 | 48 (22) | 5 (19) | 0.81 | 33 (20) | 2 (18) | 1.0 |
| Entry inhibitor | 2 (1) | 0 (0) | 1.0 | 1 (<1) | 0 (0) | 1.0 | 0 (0) | 0 (0) | 1.0 |
| Any (current/prior) use of: | |||||||||
| NRTId | 165 (99) | 25 (93) | 0.05 | 221 (99) | 25 (96) | 0.28 | 163 (98) | 10 (91) | 0.23 |
| NNRTIe | 118 (71) | 21 (78) | 0.50 | 156 (70) | 18 (69) | 1.0 | 119 (72) | 9 (82) | 0.52 |
| Protease inhibitor | 117 (70) | 23 (85) | 0.16 | 163 (73) | 20 (77) | 0.82 | 119 (72) | 7 (64) | 0.73 |
| Integrase inhibitor | 37(22) | 6 (22) | 1.0 | 48 (22) | 8 (31) | 0.32 | 34 (20) | 1 (9) | 0.47 |
| Entry inhibitor | 8 (5) | 2 (7) | 0.63 | 7 (3) | 1 (4) | 1.0 | 4 (2) | 0 (0) | 1.0 |
a
. Men whom have sex with other men,
b
. confidence interval,
c
. Veterans Aging Cohort Study,
d
. nucleoside reverse transcriptase inhibitor,
e
. non-nucleoside reverse transcriptase inhibitor